Trial Profile
A Phase II Trial In Which Patients With Metastatic Alveolar Soft Part Sarcoma Are Randomized to Either Sunitinib or Cediranib Monotherapy, With Cross-Over at Disease Progression
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 30 Nov 2023
Price :
$35
*
At a glance
- Drugs Cediranib (Primary) ; Sunitinib (Primary)
- Indications Alveolar soft part sarcoma
- Focus Therapeutic Use
- 28 Nov 2023 Planned End Date changed from 15 Mar 2024 to 15 Mar 2025.
- 21 Apr 2023 Planned End Date changed from 15 Apr 2023 to 15 Mar 2024.
- 21 Apr 2023 Planned primary completion date changed from 15 Apr 2023 to 15 Mar 2024.